TRAXENS
28.5.2019 09:02:10 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that its patented cargo tracking IoT system will be used on CFL multimodal’s connected freight wagons throughout the European corridor and the New Silk Road to China.
Traxens and CFL multimodal (CFL) started their co-operation with a pilot project at the end of 2018, when CFL fitted Traxens Box devices on flat wagons travelling between European destinations. As this initial trial was successful, it was extended earlier this year to over 20 wagons delivering cargo to more distant European destinations. In April 2019 Traxens’ rail freight telematics technology was then tested on wagons travelling to China.
As part of it digitalization strategy, CFL aims to streamline train preparation operations through automation, including digital brake testing. Traxens’ Digital Freight Train® solutions can consolidate, secure and accelerate brake safety testing. This testing system can bring a number of benefits:
- Thirty minutes saved on standard reallocation processes to improve robustness or optimize loading
- Continuous monitoring of the brake system after departure, with real-time alerts for the train driver to prevent a flat wheel
- Improved safety and working conditions for shunting and ground operators who perform brake tests
- Can be used solely by the train driver instead of two agents — reducing operating costs and improving agility and quality of the whole system
- In the longer term, it will allow the interconnection of operators systems to improve interoperability and international trade, leading to better global efficiency of rail freight
Traxens’ solution provides comprehensive, precise and timely data about cargo by tracking wagons in transit anywhere in the world. Traxens’ technology brings improved efficiency and security, greater transparency and enhanced asset utilization thanks to improved wagons and goods tracking, geolocalisation and mileage monitoring.
The Traxens Box is straightforward to install within a few minutes whether on the customers’ sites, at railway terminals or workshops; it can be adapted to any type of wagon.
“As an outcome of our joint pilot project, we are delighted that CFL multimodal decided to extend its use of our bespoke IoT technology in its rail freight operations to China,” said Florence Delalande, rail business unit director at Traxens. “This shows the potential of our technology for all rail and intermodal freight businesses, as the shipping industry shifts towards a digital future.”
“Traxens’ rail freight solution helps our operations by enabling the monitoring of assets and their surroundings, which significantly improves operational efficiency,” said Marc Valette, innovation director at CFL multimodal. “The technology used by Traxens, enabling the local interconnection of different devices without wiring, opens up new opportunities in train condition and composition monitoring. This is a huge opportunity to improve operations and service effectiveness in rail. It will allow the connection of different elements of the train ecosystem in the future, providing transparent and accurate information, improving the quality of service and information delivered to clients.”
This agreement with CFL Multimodal is the latest development for Traxens in the rail sector. Traxens has already started cooperations with other key players in the industry, such as SNCF (the French national railway company). In cooperation with SNCF Logistics, Traxens developed the Digital Freight Train and its high value-added services for the benefit of the entire railway system, by turning conventional wagons into intelligent wagons in record time. It features geolocation, arrival notifications, consignment transport conditions and status monitoring, digital assistance for wagon management, predictive maintenance and more. Traxens offers a whole range of services for a safer, more modern, eco-friendly and more efficient freight railway system.
This year Traxens has already won several innovation awards for its Digital Freight Train project.
About CFL Multimodal
CFL multimodal is a logistics service
provider, covering the entire logistics chain. With 12 companies in six
European countries, CFL multimodal and its sister company CFL cargo
offer a broad and customised service portfolio: combined and
conventional rail freight, wagon maintenance and repairs, customs
clearance, as well as forwarding and logistics services. In Luxembourg,
the activities of CFL multimodal are organised around the intermodal
terminal of Bettembourg-Dudelange on the Eurohub South Logistics Park.
Located on the Rail Freight Corridor 2 (North Sea-Mediterranean) and at
the crossroads of major transport routes, the terminal is ideally
positioned as an international hub for the consolidation of multimodal
transport flows across Europe and beyond. With a total yearly capacity
of 600,000 units and equipped with the latest technology in terms of
security and surveillance, the intermodal terminal is connected by
combined train shuttles to the main ports and industrial regions.
www.cfl-mm.lu
ABOUT TRAXENS
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The
company’s breakthrough Internet-of-Big-Things technology provides
comprehensive, real-time information for managing logistics assets
anywhere in the world. Traxens’ solutions digitally transform
multi-modal supply chains, enabling customers to reduce costs, optimize
investments, comply with environmental regulations and deliver premium
services to their customers. Traxens’ IoT solution received the Frost &
Sullivan’s Technology Leadership Award in 2019.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005138/en/
Contact:
PRESS: Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
